Changes in Botrytis cinerea Conidia Caused by Berberis vulgaris Extract

Testing plant extracts for controlling fungal diseases is a main biocontrol method. More interesting is to see what happens to the fungus treated with the plant extract. Therefore, the aim of the study was to evaluate the antifungal activity of Berberis vulgaris extract on Botrytis cinerea and to examine the ultrastructural changes in B. cinerea conidia caused by the minimum inhibitory concentration (MIC), using SEM and TEM. The antifungal activity of B. vulgaris bark extract was investigated using agar dilution method, and compared to that of berberine. Fluconazole was used as the positive antimycotic control. It was found that (1) B. vulgaris bark extract had significant antifungal activity against B. cinerea, and its effect was stronger than that of pure berberine. It was also noted that (2)B. vulgaris MIC caused severe structural changes of the conidia, comparable with berberine MIC effect; therefore (3) B. vulgaris bark extract might be recommended to be tested as a biocontrol agent against B. cinerea

SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers

The research aimed to investigate the incidence of SARS-CoV-2 breakthrough infections and their determinants in a large European cohort of more than 60,000 health workers

Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project

BackgroundThe duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs). MethodsWe analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1(st) dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses. ResultsA 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels. ConclusionsFemale gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups